keyword
MENU ▼
Read by QxMD icon Read
search

drug coated balloon angioplasty

keyword
https://www.readbyqxmd.com/read/29131504/balloon-pin-hole-rupture-during-percutaneous-coronary-intervention-for-recurrent-calcified-in-stent-restenosis-a-case-report
#1
Nobuhiro Murata, Tadateru Takayama, Takafumi Hiro, Atsushi Hirayama
Percutaneous coronary intervention (PCI) for patients with in-stent restenosis (ISR) is generally considered safe and effective. However, due to increased tissue hardness, PCI for calcified intra-stent ISR is technically challenging. Here, we report severe angioplasty-related complications in a patient presenting with calcified, recurrent ISR following PCI. After receiving drug-coated balloon (DCB) angioplasty for an initial ISR, the patient developed recurrent ISR during the follow-up period. Intravascular imaging revealed intra-stent calcifications and balloon angioplasty was subsequently performed...
November 13, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29125264/drug-coated-balloons-reduce-the-risk-of-recurrent-restenosis-in-arteriovenous-fistulas-and-prosthetic-grafts-for-hemodialysis
#2
Nicola Troisi, Pierfrancesco Frosini, Chiara Somma, Eugenio Romano, Azzurra Guidotti, Pietro C Dattolo, Giuseppe Ferro, Emiliano Chisci, Stefano Michelagnoli
BACKGROUND: Aim of this study was to evaluate the early and mid-term outcomes of drug-coated balloons (DCBs) in hemodialysis patients with recurrent stenosis of arteriovenous fistula and previously treated with plain balloon angioplasty (PBA). METHODS: Between July 2013 and June 2016 38 hemodialysis patients with recurrent stenosis of arteriovenous fistula underwent endovascular treatment with a DCB at our center. All patients were previously treated at the target lesion with a PBA...
November 10, 2017: International Angiology: a Journal of the International Union of Angiology
https://www.readbyqxmd.com/read/29078242/-drug-coated-balloon-angioplasty-in-femoropopliteal-arteries-is-there-a-class-effect
#3
Ulf Karl-Martin Teichgräber, Christof Klumb
Aim Percutaneous transluminal angioplasty (PTA) is a well-accepted method to re-establish patency in stenotic and reoccluded vessels. One tool to improve results may be to use paclitaxel drug-coated balloon (DCB) catheters. This systematic review investigates whether there is a class effect among different DCBs. Methods The primary endpoint was "Freedom from Target Lesion Revascularisation" (FfTLR) after 12 months. A systematic literature search was performed in PubMed and risk of bias was assessed of the included trials...
October 2017: Zentralblatt Für Chirurgie
https://www.readbyqxmd.com/read/29031986/endovascular-interventions-for-femoropopliteal-peripheral-artery-disease-a-network-meta-analysis-of-current-technologies
#4
REVIEW
Michael R Jaff, Teresa Nelson, Nicole Ferko, Melissa Martinson, Louise H Anderson, Sarah Hollmann
PURPOSE: To use network meta-analysis (NMA) to determine the optimal endovascular strategy for management of femoropopliteal peripheral artery disease (PAD) given the lack of multiple prospective randomized trials to guide treatment decisions. MATERIALS AND METHODS: NMA is a new meta-analytic method that permits comparisons among any 2 therapies by combining results of a collection of clinical trials conducted in the same or similar patient population. NMA was used to analyze data from 15 randomized controlled trials (RCTs) and 10 prospective, multicenter, single-arm trials (combined evidence [CE] NMA) that evaluated target lesion revascularization (TLR) for 5 endovascular strategies: bare metal stent (BMS), polymer-covered metal stent (CMS), drug-eluting stent (DES), drug-coated balloon (DCB) and percutaneous transluminal angioplasty (PTA)...
October 12, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29027735/temporal-trends-in-percutaneous-coronary-interventions-thru-the-drug-eluting-stent-era-insights-from-18-641-procedures-performed-over-12-year-period
#5
Uri Landes, Tamir Bental, Amos Levi, Abid Assali, Hana Vaknin-Assa, Eli I Lev, Eldad Rechavia, Gabriel Greenberg, Katia Orvin, Ran Kornowski
BACKGROUND: The last decade, regarded as the DES era in PCI, has witnessed significant advances in the management of coronary disease. We aimed to assess temporal trends in the practice and outcome of percutaneous coronary intervention (PCI) during the drug eluting stent (DES) era. METHODS: We analyzed 18,641 consecutive PCI's performed between January 2004 and December 2016, distinguished by procedural date (Q1 : 2004-2006, n = 4,865; Q2 : 2007-2009, n = 4,977; Q3 : 2010-2012, n = 4,230; Q4 : 2013-2016, n = 4,569)...
October 13, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28980462/treatment-of-femoropopliteal-atherosclerotic-lesions-using-the-ranger-paclitaxel-coated-balloon-catheter-12-month-results-from-an-all-comers-registry
#6
Michael Lichtenberg, Peter von Bilderling, Jürgen Ranft, Kathrin Niemöller, Holger Grell, Lucas Briner, Françoise Saucy, Tienush Rassaf, Frank Breuckmann
BACKGROUND: To evaluate 12-month effectiveness of the endovascular treatment of femoropopliteal (FP) atherosclerotic lesions with the Ranger drug-coated balloon (DCB) in a real-world setting. METHODS: In this prospective, observational, multicenter trial (ClinicalTrials.gov Identifier: NCT02462005) 172 consecutive patients with 226 de novo, restenosed, or reoccluded native superficial femoral and/or popliteal artery lesions were treated with the Ranger paclitaxel- coated balloon angioplasty...
October 3, 2017: Journal of Cardiovascular Surgery
https://www.readbyqxmd.com/read/28975778/debulking-plus-drug-coated-balloon-combination-as-revascularization-strategy-for-complex-femoropopliteal-lesions
#7
Katia Dessi, Luca Giovannacci, Jos C Vand den Berg
This paper will discuss the results from the most recent randomized trials and large registries for DCB's and atherectomy, and the drawbacks of these 2 therapeutic options. It will also discuss the results of combination therapy in complex femoropopliteal lesions. Several studies indicate that combining atherectomy and DCB yields better outcomes in complex calcified lesions, but the only randomized pilot study could not demonstrate a benefit of combination therapy in the mid-term follow-up. Larger, randomized studies are needed to define the role of atherectomy followed by DCB angioplasty further...
October 2, 2017: Journal of Cardiovascular Surgery
https://www.readbyqxmd.com/read/28975777/the-evolving-role-of-drug-coated-balloons-for-the-treatment-of-complex-femoropopliteal-lesions
#8
Grigorios Korosoglou, Michael Lichtenberg, Sultan Celik, Joachim Andrassy, Marianne Brodmann, Martin Andrassy
INTRODUCTION: Conventional therapies for transcatheter treatment of patients with infrainguinal obstructive disease remain compromised by high restenosis rates. Drug-coated balloons (DCB) offer a novel therapeutic alternative targeting the source of neo-intimal hyperplasia, without the need for a permanent endovascular scaffold and their inherent limitations. EVIDENCE ACQUISITION: A systematic research of the medical databases (Pubmed) has been conducted for this up-to-date review...
October 2, 2017: Journal of Cardiovascular Surgery
https://www.readbyqxmd.com/read/28966454/endovascular-therapy-of-axillary-artery-disease-with-drug-coated-balloon-angioplasty
#9
Subhi J Al'Aref, Rajesh V Swaminathan, Dmitriy N Feldman
The occurrence of upper-extremity arterial disease is less common than that of the lower extremities. Nevertheless, exercise-induced symptoms, when present, can significantly affect functional capacity and limit quality of life. We report a case of exertional right upper-extremity pain and severe right axillary artery disease that was revascularized using an off-label drug-coated balloon technology with resolution of symptoms.
October 2017: Proceedings of the Baylor University Medical Center
https://www.readbyqxmd.com/read/28964764/the-sabre-trial-sirolimus-angioplasty-balloon-for%C3%A2-coronary-in-stent-restenosis-angiographic-results-and-1-year-clinical-outcomes
#10
Stefan Verheye, Mathias Vrolix, Indulis Kumsars, Andrejs Erglis, Dace Sondore, Pierfrancesco Agostoni, Kristoff Cornelis, Luc Janssens, Michael Maeng, Ton Slagboom, Giovanni Amoroso, Lisette Okkels Jensen, Juan F Granada, Pieter Stella
OBJECTIVES: The aim of this first-in-human study was to assess the safety and effectiveness of the Virtue sirolimus-eluting balloon in a cohort of patients with in-stent restenosis (ISR). BACKGROUND: Angioplasty balloons coated with the cytotoxic drug paclitaxel have been widely used for ISR treatment. The Virtue angioplasty balloon (Caliber Therapeutics, New Hope, Pennsylvania) delivers sirolimus in a nanoencapsulated liquid formulation. This clinical trial is the first to examine a sirolimus-eluting balloon for ISR...
September 19, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28958476/cost-effectiveness-analysis-of-drug-coated-therapies-in-the-superficial-femoral-artery
#11
REVIEW
Natalie D Sridharan, Aureline Boitet, Kenneth Smith, Kathy Noorbakhsh, Efthymios Avgerinos, Mohammad H Eslami, Michel Makaroun, Rabih Chaer
OBJECTIVE: Drug-coated balloons (DCBs) may increase durability of endovascular treatment of superficial femoral artery (SFA) disease while avoiding stent-related risks. The purpose of this study was to use meta-analytic data of DCB studies to compare the cost-effectiveness of potential SFA treatments: DCB, drug-eluting stent (DES), plain old balloon angioplasty (POBA), or bare-metal stent (BMS). METHODS: A search for randomized controlled trials comparing DCB with POBA for treatment of SFA disease was performed...
September 25, 2017: Journal of Vascular Surgery
https://www.readbyqxmd.com/read/28933522/drug-coated-balloons-in-the-superficial-femoral-artery
#12
Oliver Schlager, Michael E Gschwandtner, Andrea Willfort-Ehringer, Florian Wolf, Christian Loewe, Renate Koppensteiner, Michael Lichtenberg
Despite the progress in endovascular treatment of patients with peripheral arterial disease, restenosis remains the major drawback, especially in patients with femoropopliteal lesions. To reduce neointimal proliferation and subsequent restenosis the use of antiproliferative drug eluting devices was implemented in the endovascular treatment of femoropopliteal disease. Aiming to use the favorable effects of these antiproliferative agents and to reduce foreign body exposure in affected arteries, drug coated balloons (DCB) have been developed...
September 20, 2017: Journal of Cardiovascular Surgery
https://www.readbyqxmd.com/read/28916429/incidence-and-predictors-of-recurrent-restenosis-after-drug-coated-balloon-angioplasty-for-restenosis-of-a-drug-eluting-stent-the-icarus-cooperation
#13
Salvatore Cassese, Bo Xu, Seiji Habara, Harald Rittger, Robert A Byrne, Matthias Waliszewski, María José Pérez-Vizcayno, Runlin Gao, Adnan Kastrati, Fernando Alfonso
INTRODUCTION AND OBJECTIVES: The incidence and predictors of recurrent restenosis after drug-coated balloon (DCB) angioplasty for drug-eluting stent (DES) restenosis remain poorly studied. We sought to evaluate the incidence and predictors of recurrent restenosis among participants in randomized controlled trials receiving DCB angioplasty for DES restenosis. METHODS: The clinical and lesion data of individuals enrolled in 6 randomized controlled trials of DCB angioplasty for DES restenosis were pooled...
September 12, 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/28844032/state-of-the-art-coronary-artery-stents-past-present-and-future
#14
Giulio G Stefanini, Robert A Byrne, Stephan Windecker, Adnan Kastrati
The first percutaneous coronary intervention (PCI) was performed in September 1977 by Andreas Grüntzig using a rudimentary balloon angioplasty catheter mounted on a fixed wire. PCI was immediately recognised as a potential breakthrough in cardiovascular medicine, but uptake in clinical practice was limited by unpredictable acute outcomes and a need for surgical standby. The introduction of bare metal stents (BMS) in the 1980s improved procedure reproducibility and clinical outcomes through a permanent scaffolding of the coronary vessel, preventing abrupt occlusion and acute recoil...
August 25, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28844030/state-of-the-art-balloon-catheter-technologies-drug-coated-balloon
#15
Fernando Alfonso, Bruno Scheller
Four decades after its introduction into clinical practice, coronary balloon angioplasty is still used during most coronary interventions. Conventional balloon angioplasty is frequently used to predilate complex or severe lesions and remains of major value to optimise the results of stent implantation. Plain balloon angioplasty is still used alone in some anatomic scenarios where stent implantation is not desirable (very small vessels or diffuse lesions, large resistant thrombus burden, side branches of bifurcations)...
August 25, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28840466/advances-in-percutaneous-therapies-for-peripheral-artery-disease-drug-coated-balloons
#16
REVIEW
Rasha F Al-Bawardy, Stephen W Waldo, Kenneth Rosenfield
PURPOSE OF REVIEW: This review paper provides a summary on the use of drug-coated balloons in peripheral artery disease. It covers the main drug-coated balloon (DCB) trials. It is divided into categories of lesions: superficial femoral artery and popliteal lesions, infra-popliteal lesions and in-stent restenosis. It also includes an overview of the future of DCBs, highlighting the main ongoing trials. RECENT FINDINGS: The latest research on DCB focuses on newer types of DCBs, mainly paclitaxel-coated but with lower doses...
August 24, 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/28837370/drug-delivering-endovascular-treatment-versus-angioplasty-in-artery-occlusion-diseases-a-systematic-review-and-meta-analysis
#17
Xudong Chen, Jianhui Li, Chengfei Zheng, Yunjun He, Junjun Jia, Xiaohui Wang, Donglin Li, Tao Shang, Ming Li
OBJECTIVE: The best management of patients with femoropopliteal and infrapopliteal artery occlusion disease is not clear. This study aimed to compare the efficacy of drug-coated balloons (DCB) and drug-eluting stents (DES) with percutaneous transluminal angioplasty (PTA) in patients with femoropopliteal or infrapopliteal arterial occlusive disease. METHODS: Medline, Cochrane, EMBASE, and Google Scholar databases were searched for randomized controlled trials from January 1, 2000 until June 30, 2016...
August 24, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28780030/the-24-month-results-of-the-lutonix%C3%A2-global-sfa-registry-worldwide-experience-with%C3%A2-lutonix%C3%A2-drug-coated-balloon
#18
Marcus Thieme, Peter Von Bilderling, Christian Paetzel, Dimitrios Karnabatidis, Julio Perez Delgado, Michael Lichtenberg
OBJECTIVES: The Global SFA Registry sought to assess safety, clinical benefit, and outcomes of the Lutonix 035 drug-coated balloon (DCB) in a heterogeneous, real-world patient population at 12 and 24 months. BACKGROUND: Numerous clinical studies have evaluated the use of angioplasty for revascularization of femoropopliteal arteries in peripheral arterial disease with restenosis rates of 40% to 60% at 6 to 12 months. Data from recent studies document decreased restenosis rates and improvement in patency in patients receiving angioplasty of femoropopliteal arteries with DCBs...
August 28, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28779784/drug-coated-balloon-angioplasty-for-dialysis-access-fistula-stenosis
#19
REVIEW
Auréline Boitet, Ziad A Massy, Olivier Goeau-Brissonniere, Isabelle Javerliat, Marc Coggia, Raphaël Coscas
Maintaining vascular access patency represents a tremendous challenge in hemodialysis patients. Although "native" arteriovenous fistula (AVF) is currently recommended as primary vascular access, neointimal hyperplasia stenoses frequently develop, with a risk for AVF thrombosis and vascular access loss. For years, first-line treatment of AVFs stenoses has been percutaneous transluminal angioplasty, generally with high-pressure or cutting uncoated balloons. However, restenosis and reintervention rates remain incredibly high and occur, according to recent studies, in up to 60% and 70% of patients at 6 and 12 months, respectively...
December 2016: Seminars in Vascular Surgery
https://www.readbyqxmd.com/read/28729250/stellarex-drug-coated-balloon-for-treatment-of-femoropopliteal-disease-twelve-month-outcomes-from-the-randomized-illumenate-pivotal-and-pharmacokinetic-studies
#20
RANDOMIZED CONTROLLED TRIAL
Prakash Krishnan, Peter Faries, Khusrow Niazi, Ash Jain, Ravish Sachar, William B Bachinsky, Joseph Cardenas, Martin Werner, Marianne Brodmann, J A Mustapha, Carlos Mena-Hurtado, Michael R Jaff, Andrew H Holden, Sean P Lyden
BACKGROUND: Drug-coated balloons (DCBs) are a predominant revascularization therapy for symptomatic femoropopliteal artery disease. Because of the differences in excipients, paclitaxel dose, and coating morphologies, varying clinical outcomes have been observed with different DCBs. We report the results of 2 studies investigating the pharmacokinetic and clinical outcomes of a new DCB to treat femoropopliteal disease. METHODS: In the ILLUMENATE Pivotal Study (Prospective, Randomized, Single-Blind, U...
September 19, 2017: Circulation
keyword
keyword
102043
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"